Locations:
Search IconSearch
February 15, 2022/Cancer

Let’s Talk About Childhood Cancer Survivorship (Podcast)

Seth Rotz, MD, joins the Cancer Advances podcast to share insights

22-CHP-2736512 CQD Rotz – Childhood Cancer Survivorship-Podcast-Hero 650×450

More children are surviving childhood cancers than ever before. Each year in the United States about 15,000 children are diagnosed with cancer, and about 80% to 85% will survive five years or longer.

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

While these numbers are encouraging, pediatric oncologists say a shift to better longer-term management of pediatric cancer survivors is warranted. The Childhood Cancer Survivorship Program at Cleveland Clinic Children’s is focused on doing just that.

Led by pediatric hematologist/oncologist Seth Rotz, MD, the physicians work with pediatric cancer survivors, their families, and other subspecialists as needed to identify risks and monitor late effects associated with disease and its treatment. They also provide counsel and resources related to other concerns, such as family planning and psychosocial issues.

Dr. Rotz joined the Cancer Advances podcast to discuss the goals of the program, the biggest issues in childhood cancer survivorship programs, and the next exciting thing in the field.

An excerpt from the podcast

“Our focus in cancer survivorship has focused a great deal on the medical effects of having received chemotherapy and radiation. And, I think, in the last several years, there’s just been more attention focused on questions like: What are the long-term psychological impacts? What are the financial impacts of having had cancer? Does this impact whether a teenager ends up applying to college or not? Or does it put somebody in a position where they can’t change jobs because they’re worried about health insurance coverage and so forth,” he says.

“And then we have so many people and parents, too, who have some degree of post-traumatic stress from their treatment, and so we are trying to identify different mental health issues that can go along with treatment and get people plugged in with the resources they need, which is another very important part of what we do.”

Advertisement

Featured in Cleveland Clinic Children's 2022 Year in Review

Advertisement

Related Articles

Doctors working on MGUS screening study
March 18, 2024/Cancer/Research
Pilot Study Aims for Early Identification of Multiple Myeloma Precursor Among Black Patients

First-of-its-kind research investigates the viability of standard screening to reduce the burden of late-stage cancer diagnoses

Hematologist at Cleveland Clinic
March 14, 2024/Cancer/Blood Cancers
Advances in Mantle Cell Lymphoma Treatment (Podcast)

Global R&D efforts expanding first-line and relapse therapy options for patients

Physician with patient
March 6, 2024/Cancer/Research
Targeting Uncontrolled Erythrocytosis in Polycythemia Vera with Rusfertide

Study demonstrates ability to reduce patients’ reliance on phlebotomies to stabilize hematocrit levels

Dr. Jagadeesh at Cleveland Clinic
February 28, 2024/Cancer/Blood Cancers
Treating Patient with Systemic T-Cell Lymphoma and Graft-Versus-Host Disease

A case study on the value of access to novel therapies through clinical trials

Doctor measuring patient's waist size
February 26, 2024/Cancer/Research
Impact of Obesity on GVHD & Transplant Outcomes in Hematologic Malignancies

Findings highlight an association between obesity and an increased incidence of moderate-severe disease

Physician with patient
February 21, 2024/Cancer/Research
Strategies for Improving Clinical Trial Equity

Cleveland Clinic Cancer Institute takes multi-faceted approach to increasing clinical trial access 23456

How antibody drug conjugates work
February 13, 2024/Cancer/Research
Real-World Use of Trastuzumab Deruxtecan

Key learnings from DESTINY trials

CQD-4445459-rotz-650×450
February 7, 2024/Cancer
Advances in Bone Marrow Transplant Have Improved Outcomes in Fanconi Anemia

Overall survival in patients treated since 2008 is nearly 20% higher than in earlier patients

Ad